Hydrogenology
Hydrogenology editorial study record

Protection by Inhaled Hydrogen Therapy in a Rat Model of Acute Lung Injury Can Be Tracked in Vivo Using Molecular Imaging

Audi SH, Jacobs ER, Zhang X, Camara AKS, Zhao M, Medhora M, Rizzo B, Clough AV. · Shock. 2017;48(4):467-476.

PreclinicalInhaled H₂Published 2017
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled time-course hyperoxia experiment with blinded histology and in-vivo molecular imaging subsets

Research topic

Respiratory health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adult male Sprague-Dawley rats exposed to room air, 98% O₂ plus 2% N₂, or 98% O₂ plus 2% H₂.

Sample

181 rats overall: normoxia n=42, hyperoxia n=77 and hyperoxia plus H₂ n=62. Different histology, biochemical and imaging outcomes used prespecified random subsets.

Duration

Continuous 24-, 48- or 60-hour exposure, with outcome-specific assessments and imaging.

Intervention

Continuous chamber exposure to 98% O₂ plus 2% H₂ for 24, 48 or 60 hours.

Hydrogen form

Inhaled premixed H₂/O₂ gas — not Brown's gas: the source mixture was 2% H₂ and 98% O₂, not the 2:1 H₂:O₂ ratio.

H₂ specification

The chamber measured >1.8% H₂ and >96% O₂. The article does not report total chamber gas flow, so H₂ and O₂ mL/min cannot be calculated.

H₂ flow

Not reported — no total mixture flow or H₂ mL/min is provided.

O₂ delivered with H₂

Nominal 98% O₂ (measured >96%), but O₂ mL/min is not reportable without total gas flow.

Comparator

Room-air normoxia and 98% O₂ plus 2% N₂ hyperoxia groups at matching exposure times.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Body/lung weights, edema and pleural effusion, histology, lavage protein/cells, oxidative markers, mitochondrial membrane recovery, glutathione, and SPECT HMPAO/duramycin uptake.

Reported result

H₂ reduced several imaging, oxidative, inflammatory and pleural-effusion changes and partially protected mitochondrial recovery. It did not improve body-weight change at 24 or 60 hours, did not significantly reduce lung wet-weight/body-weight rise, produced a higher 24-hour wet/dry ratio than hyperoxia alone, and did not change 4-HNE; results differed from some prior rat studies.

Results-extraction completeness

The complete free PMC author manuscript was checked for all exposure groups and totals, gas composition/measurements, time points, imaging and tissue outcomes, positive and null findings, funding and available disclosure section.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical hyperoxia model with continuous near-pure-oxygen exposure unlike many clinical contexts, outcome-specific subsets, numerous comparisons, no reported total gas flow and some findings inconsistent with earlier studies. NIH, VA and foundation support was reported; no explicit author conflict statement was identified, so absence is not inferred.

Applies directly to

Hyperoxia-induced lung injury in adult male rats; it does not establish inhaled H₂ treatment for human ALI/ARDS.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 28915216 · DOI: 10.1097/SHK.0000000000000872

Publisher access

Free full author manuscript in PubMed Central.

Extraction basis

Complete PMC author manuscript and PubMed metadata; full-text extraction checked 9 August 2026.

Record revision

2026-08-10